Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
L01EX15
|
| gptkbp:brand |
Xospata
|
| gptkbp:CASNumber |
1254053-43-4
|
| gptkbp:developedBy |
gptkb:Astellas_Pharma
|
| gptkbp:hasMolecularFormula |
C29H44N8O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
gilteritinib
|
| gptkbp:indication |
relapsed or refractory FLT3-mutated AML
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
QT prolongation
liver toxicity differentiation syndrome |
| gptkbp:target |
gptkb:FLT3
gptkb:AXL |
| gptkbp:usedFor |
gptkb:acute_myeloid_leukemia
|
| gptkbp:bfsParent |
gptkb:FLT3_mutation
|
| gptkbp:bfsLayer |
6
|